Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 1/20 | 0.34 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25695967 | 1.00 | PLA2G10 (0.34) | PLA2G10PLA2G5MEN1KMT2ANPSR1 | |
| SCHEMBL18915827 | 0.89 | PSMB8 (0.32) | PLA2G10PLA2G5 | |
| SCHEMBL15984351 | 0.87 | CYP2D6 (0.35) | PLA2G10PLA2G5KMT2AMGLLKDM4E | |
| SCHEMBL18219407 | 0.87 | CYP2D6 (0.35) | PLA2G10PLA2G5KMT2AMGLLKDM4E | |
| SCHEMBL13682852 | 0.86 | PSMB8 (0.33) | KMT2AMGLLALDH1A1 | |
| SCHEMBL21361052 | 0.86 | LTA4H (0.33) | PLA2G10PLA2G5 | |
| SCHEMBL18218906 | 0.83 | PLA2G10 (0.33) | PLA2G10PLA2G5 | |
| SCHEMBL13265369 | 0.82 | CYP1A2 (0.40) | MEN1KMT2ANPSR1 | |
| SCHEMBL3749003 | 0.82 | CYP1A2 (0.40) | MEN1KMT2ANPSR1 | |
| SCHEMBL8740492 | 0.82 | STING1 (0.34) | PLA2G10PLA2G5KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | PLA2G10 3394/4885PLA2G5 2687/4885MEN1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.